for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-FDA Accepts Genentech's Supplemental New Drug Application For Xofluza

March 6 (Reuters) - Genentech:

* FDA ACCEPTS GENENTECH’S SUPPLEMENTAL NEW DRUG APPLICATION FOR XOFLUZA (BALOXAVIR MARBOXIL) FOR THE TREATMENT OF INFLUENZA IN PEOPLE AT HIGH RISK OF COMPLICATIONS

* GENENTECH- XOFLUZA WOULD BE FIRST ANTIVIRAL MEDICINE APPROVED SPECIFICALLY FOR HIGH-RISK POPULATION

* GENENTECH - FDA IS EXPECTED TO MAKE A DECISION ON APPROVAL BY NOVEMBER 4, 2019 Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up